The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research

Mass Spectrometry Reviews

Volumn 27, Issue 2, 2008, Pages 67-100

  Brouwers, Elke E M ^a   Tibben, Matthijs ^a   Rosing, H ^a   Schellen, Jan H M ^b,c   Beijnen, Jos H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Anticancer drugs; Applications; Bioanalysis; ICP MS; Platinum; Ruthenium

Indexed keywords

LIQUID CHROMATOGRAPHY; METABOLISM; ONCOLOGY; PHARMACOKINETICS; TUMORS;

ANTICANCER DRUGS; CLINICAL PHARMACOLOGICAL ONCOLOGY;

INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY;

ANTINEOPLASTIC AGENT; PLATINUM; PLATINUM COMPLEX; RUTHENIUM;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; HUMAN; MEDICAL RESEARCH;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; HUMANS; ORGANOPLATINUM COMPOUNDS; PLATINUM; RUTHENIUM; SPECTROPHOTOMETRY, ATOMIC;

EID: 39849095464     PISSN: 02777037     EISSN: None     Source Type: Journal    
DOI: 10.1002/mas.20159     Document Type: Article

References (173)

1. Alessio E, Mestroni G, Bergamo A, Sava G. 2004. Ruthenium antimetastatic agents. Curr Top Med Chem 4:1525-1535.
2. Allain P, Berre S, Mauras Y, Le Bouil A. 1992. Evaluation of inductively coupled mass spectrometry for the determination of platinum in plasma. Biol Mass Spectrom 21:141-143.
3. Allain P, Heudi O, Cailleux A, Le Bouil A, Larra F, Boisdron-Celle M, Gamelin E. 2000. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 28:1379-1384.
4. Azim-Araghi A, Ottley CJ, Pearson DG, Tilby MJ. 2001. Sensitive detection of platinum-bound DNA using ICP-MS and comparison to graphite furnace atomic absorption spectroscopy (GFAAS). In: Holland JG, Tanner SD, editors. Plasma source mass spectrometry. Cambridge, UK: Royal Society of Chemistry, pp. 412-418.
5. Azim-Araghi A, Ottley CJ, Pearson DG, Tilby MJ. 2003. Combination of ICP-MS and ion exchange chromatography permits analyses of specific cisplatin DNA modifications formed in cancer cells. In: Holland JG, Tanner SD, editors. Plasma source mass spectrometry. Cambridge, UK: Royal Society of Chemistry, pp. 66-73.
6. Barefoot RR. 1997. Determination of platinum at trace levels in environmental and biological samples. Environ Sci Technol 31:309-314.
7. Bell DN, Liu JJ, Tingle MD, McKeage MJ. 2006. Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 837:29-34.
8. Bettinelli M, Spezia S, Ronchi A, Minoia C. 2004. Determination of Pt in biological fluids with ICP-MS: Evaluation of analytical uncertainty. Atom Spectrosc 25:103-111.
9. Bible KC, Boerner SA, Kirkland K, Anderl KL, Bartelt D Jr, Svingen PA, Kottke TJ, Lee YK, Eckdahl S, Stalboerger PG, Jenkins RB, Kaufmann SH. 2000. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res 6:661-670.
10. Bings NH. 2005. Plasma time-of-flight mass spectrometry as a detector for short transient signals in elemental analysis. Anal Bioanal Chem 382: 887-890.
11. Bjorn E, Nygren Y, Nguyen TT, Ericson C, Nojd M, Naredi P. 2007. Determination of platinum in human subcellular microsamples by inductively coupled plasma mass spectrometry. Anal Biochem 363: 135-142.
12. Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R. 1996. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Clin Cancer Res 2:1829-1835.
13. Bose RN. 2002. Biomolecular targets for platinum antitumor drugs. Mini Rev Med Chem 2:103-111.
14. Boulikas T, Vougiouka M. 2003. Cisplatin and platinum drugs at the molecular level (Review). Oncol Rep 10:1663-1682.
15. Bouma M, Nuijen B, Jansen MT, Sava G, Picotti F, Flaibani A, Bult A, Beijnen JH. 2003. Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A. J Pharm Biomed Anal 31:215-228.
16. Brandsteterova E, Kiss F, Chovancova V, Reichelova V. 1991. HPLC analysis of platinum cytostatics. Neoplasma 38:415-424.
17. Brouwers EEM, Tibben MM, Rosing H, Hillebrand MJX, Joerger M, Schellens JHM, Beijnen JH. 2006. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J Mass Spectrom 41:1186-1194.
18. Brouwers EEM, Huitema ADR, Bakker EN, Douma JW, Schimmel KJ, van Weringh G, de Wolf PJ, Schellens JHM, Beijnen JH. 2007a. Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry. Int Arch Occup Environ Health 80:689-699.
19. Brouwers EEM, Huitema ADR, Beijnen JH, Schellens JHM. 2007b. Long-term platinum retention after treatment with cisplatin and oxaliplatin. (submitted).
20. Brouwers EEM, Tibben MM, Rosing H, Schellens JHM, Beijnen JH. 2007c. Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry. Rapid Commun Mass Spectrom 21:1521-1530.
21. Cairns WRL, Ebdon L, Hill SJ. 1994. Development of an HPLC-ICP-MS method for the determination of platinum species from new anti-tumour drugs. Anal Proc Incl Anal Commun 31:295-297.
22. Cairns WR, Ebdon L, Hill SJ. 1996. A high performance liquid chromatography-Inductively coupled plasma-mass spectrometry interface employing desolvation for speciation studies of platinum in chemotherapy drugs. Anal Bioanal Chem 355:202-208.
23. Calvert H, Judson I, van der Vijgh WJ. 1993. Platinum complexes in cancer medicine: Pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv 17:189-217.
24. Carr JL, Tingle MD, McKeage MJ. 2002. Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother Pharmacol 50:9-15.
25. Casetta B, Roncadin M, Montanari G, Fulanut M. 1991. Determination of platinum in biological fluids by ICP-mass spectrometry. Atomic Spectrosc 12:81-86.
26. Centerwall CR, Tacka KA, Kerwood DJ, Goodisman J, Toms BB, Dubowy RL, Dabrowiak JC. 2006. Modification and uptake of a cisplatin carbonato complex by Jurkat cells. Mol Pharmacol 70:348-355.
27. Charlier C, Kintz P, Dubois N, Plomteux G. 2004. Fatal overdosage with cisplatin. J Anal Toxicol 28:138-140.
28. Cooper BW, Veal GJ, Radivoyevitch T, Tilby MJ, Meyerson HJ, Lazarus HM, Koc ON, Creger RJ, Pearson G, Nowell GM, Gosky D, Ingalls ST, Hoppel CL, Gerson SL. 2004. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. Clin Cancer Res 10:6830-6839.
29. Crul M, van den Bongard HJ, Tibben MM, van Tellingen O, Sava G, Schellens JH, Beijnen JH. 2001. Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 369:442-445.
30. Dams RFJ, Goossens J, Moens L. 1995. Spectral and non-spectral interferences in inductively coupled plasma mass-spectrometry. Mikrochim Acta 119:286.
31. De Boer JL, Ritsema R, Piso S, Van Staden H, Van Den BW. 2004. Practical and quality-control aspects of multi-element analysis with quadrupole ICP-MS with special attention to urine and whole blood. Anal Bioanal Chem 379:872-880.
32. De Waal WA, Maessen FJ, Kraak JC. 1990. Analytical methodologies for the quantitation of platinum anti-cancer drugs and related compounds in biological media. J Pharm Biomed Anal 8:1-30.
33. Desoize B, Madoulet C. 2002. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42:317-325.
34. Ding H, Goldberg MM, Raymer JH, Holmes J, Stanko J, Chaney SG. 1999. Determination of platinum in rat dorsal root ganglion using ICP-MS. Biol Trace Elem Res 67:1-11.
35. Dominici C, Alimonti A, Caroli S, Petrucci F, Castello MA. 1986. Chemotherapeutic agent cisplatin monitoring in biological fluids by means of inductively-coupled plasma emission spectrometry (ICP-AES). Clin Chim Acta 158:207-215.
36. Eastman A. 1987. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34:155-166.
37. Ehrsson H, Wallin I. 2003. Liquid chromatographic determination of oxaliplatin in blood using post-column derivatization in a microwave field followed by photometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 795:291-294.
38. Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, Laurell G. 2004. High-dose Cisplatin with amifostine: Ototoxicity and pharmacokinetics. Laryngoscope 114:1660-1667.
39. El Khateeb M, Appleton TG, Charles BG, Gahan LR. 1999. Development of HPLC conditions for valid determination of hydrolysis products of cisplatin. J Pharm Sci 88:319-326.
40. Evans HE, Giglio JJ. 1993. Interferences in inductively coupled plasma mass spectrometry - A review. J Anal Atom Spectrom 8:18.
41. Falter R, Wilken RD. 1999. Determination of carboplatinum and cisplatinum by interfacing HPLC with ICP-MS using ultrasonic nebulisation. Sci Total Environ 225:167-176.
42. Feldmann I, Jakubowski N, Thomas C, Struewer D. 1999. Application of a hexapole collision and reaction cell in ICP-MS. Part II: Analytical figures of merit and first applications. Fresenius J Anal Chem 365:422-428.
43. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J. 1985. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation. Biochemistry 24:707-713.
44. Filippich LJ, Bucher AM, Charles BG. 2000. Platinum pharmacokinetics in sulphur-crested cockatoos (Cacatua galerita) following single-dose cisplatin infusion. Aust Vet J 78:406-411.
45. Filippich LJ, Charles BG, Sutton RH, Bucher AM. 2004. Carboplatin pharmacokinetics following a single-dose infusion in sulphur-crested cockatoos (Cacatua galerita). Aust Vet J 82:366-369.
46. Galettis P, Carr L, Paxton JW, McKeage MJ. 1999. Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation. J Anal Atom Spectrom 14:953-956.
47. Gamelin E, Allain P, Maillait P, Turcant A, Delva R, Lortholary A, Larra F. 1995. Long-term pharmacokinetic behavior of platinum after cisplatin administration. Cancer Chemother Pharmacol 37:97-102.
48. Gamelin E, Bouil AL, Boisdron-Celle M, Turcant A, Delva R, Cailleux A, Krikorian A, Brienza S, Cvitkovic E, Robert J, Larra F, Allain P. 1997. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 3:891-899.
49. Gamelin E, Boisdron-Celle M, Lebouil A, Turcant A, Cailleux A, Krikorian A, Brienza S, Cvitkovic E, Larra F, Robert J, Allain P. 1998. Determination of unbound platinum after oxaliplatin administration: Comparison of currently available methods and influence of various parameters. Anticancer Drugs 9:223-228.
50. Garcia Sar D, Montes-Bayon M, Blanco Gonzalez E, Sanz-Medel A. 2006. Speciation studies of cisplatin adducts with DNA nucleotides via elemental specific detection (P and Pt) using liquid chromatography-inductively coupled plasma-mass spectrometry and structural characterization by electrospray mass spectrometry. J Anal Atom Spectrom 21:861-868.
51. Gelevert T, Messerschmidt J, Meinardi MT, Alt F, Gietema JA, Franke JP, Sleijfer DT, Uges DR. 2001. Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin. Ther Drug Monit 23:169-173.
52. Gerl A, Schierl R. 2000. Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. Acta Oncol 39: 519-522.
53. Ghezzi A, Aceto M, Cassino C, Gabano E, Osella D. 2004. Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS). J Inorg Biochem 98:73-78.
54. Giessmann U, Greb U. 1994. High resolution ICP-MS - A new concept for elemental mass spectrometry. Fresenius J Anal Chem 350:186-193.
55. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, Sleijfer DT. 2000. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 355:1075-1076.
56. Gorodetsky R, Mou X, Vexier A, Kaufman B, Catane R, Loewenthal E. 1993. Noninvasive follow-up of platinum pharmacokinetics in the skin of patients on cisplatin chemotherapy. Cancer 72:446-454.
57. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. 2000. Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 6:1205-1218.
58. Guerbet M, Goulle JP, Lubrano J. 2007. Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol 33(5):623-626.
59. Hanada T, Isobe H, Saito T, Ogura S, Takekawa H, Yamazaki K, Tokuchi Y, Kawakami Y. 1998a. Intracellular accumulation of thallium as a marker of cisplatin cytotoxicity in nonsmall cell lung carcinoma: An application of inductively coupled plasma mass spectrometry. Cancer 83:930-935.
60. Hanada T, Isobe H, Saitoh T, Ogura S, Saito K, Kawakami Y. 1998b. Inductively coupled plasma mass spectrometry for the determination of platinum accumulation in human non-small cell lung cancer cell lines. Int J Clin Oncol 3:98-101.
61. Hann S, Zenker A, Galanski M, Bereuter TL, StingederG, Keppler BK. 2001. HPIC-UV-ICP-SFMS study of the interaction of cisplatin with guanosine monophosphate. Fresenius J Anal Chem 370:581-586.
62. Hann S, Koellensperger G, Kanitsar K, Stingeder G, Brunner M, Erovic B, Muller M, Reiter C. 2003a. Platinum determination by inductively coupled plasma-sector field mass spectrometry (ICP-SFMS) in different matrices relevant to human biomonitoring. Anal Bioanal Chem 376: 198-204.
63. Hann S, Koellensperger G, Stefanka Z, Stingeder G, Furhacker M, Buchberger W, Mader RM. 2003b. Application of HPLC-ICP-MS to speciation of cisplatin and its degradation products in water containing different chloride concentrations and in human urine. J Anal Atom Spectrom 18:1391-1395.
64. Hann S, Stefanka Z, Lenz K, Stingeder G. 2005. Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC-ICP-MS. Anal Bioanal Chem 381:405-412.
65. Hartinger CG, Hann S, Koellensperger G, Sulyok M, Groessl M, Timerbaev AR, Rudnev AV, Stingeder G, Keppler BK. 2005. Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins - Significance for the patient. Int J Clin Pharmacol Ther 43: 583-585.
66. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK. 2006. From bench to bedside - Preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III) ] (KP1019 or FFC14A). J Inorg Biochem 100:891-904.
67. Heudi O, Cailleux A, Allain P. 1998. Kinetic studies of the reactivity between cisplatin and its monoaquo species with L-methionine. J Inorg Biochem 71:61-69.
68. Heudi O, Brisset H, Cailleux A, Allain P. 2001. Chemical instability and methods for measurement of cisplatin adducts formed by interactions with cysteine and glutathione. Int J Clin Pharmacol Ther 39:344-349.
69. Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, Wyrick SD, Chaney SG. 1998. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46:342-351.
70. Hsiung CS, Andrade JD, Costa R, Ash KO. 1997. Minimizing interferences in the quantitative multielement analysis of trace elements in biological fluids by inductively coupled plasma mass spectrometry. Clin Chem 43:2303-2311.
71. Jamieson SM, Liu J, Hsu T, Baguley BC, McKeage MJ. 2003. Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. Br J Cancer 88:1942-1947.
72. Jarvis KE, Gray AL, Houk RS. 1992. Handbook of inductively coupled plasma mass spectrometry. London: Blackie Academic & Professional.
73. John T, Ottley CJ, Pearson DG, Nowell GM, Calvert H, Tilby MJ. 2003. Determination, by ICP-MS, of background and BBR 3464 induced levels of platinum bound to DNA isolated from blood cells: A comparison of the sensitivity of the perkin elmer sciex elan 6000 and the thermofinnigan neptune instruments. In: Holland JG, Tanner SD, editors. Plasma source spectrometry. Cambridge, UK: Royal Society of Chemistry, pp. 82-90.
74. Johnsson A, Bjork H, Schutz A, Skarby T 1998. Sample handling for determination of free platinum in blood after cisplatin exposure. Cancer Chemother Pharmacol 41:248-251.
75. Jonson R, Mattsson S, Unsgaard B. 1988. A method for in vivo analysis of platinum after chemotherapy with cisplatin. Phys Med Biol 33:847-857.
76. Kelland L. 2007. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573-584.
77. Khalaila I, Bergamo A, Bussy F, Sava G, Dyson PJ. 2006. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. Int J Oncol 29:261-268.
78. Kolb RJ, Ghazi AM, Barfuss DW. 2003. Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl- L-cysteine-cDDP by TEA and PAH in the renal proximal tubule. Cancer Chemother Pharmacol 51:132-138.
79. Kratz F, Hartmann M, Keppler B, Messori L. 1994. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J Biol Chem 269:2581-2588.
80. Krull IS, Ding XD, Braverman S, Selavka C, Hochberg F, Sternson LA. 1983. Trace analysis for cis-platinum anti-cancer drugs via LCEC. J Chromatogr Sci 21:166-173.
81. Lardinois D, Jung FJ, Opitz I, Rentsch K, Latkoczy C, Vuong V, Varga Z, Rousson V, Gunther D, Bodis S, Stahel R, Weder W. 2006. Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J Thorac Cardiovasc Surg 131:697-703.
82. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. 2006. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12:3050-3056.
83. Lenz K, Hann S, Koellensperger G, Stefanka Z, Stingeder G, Weissenbacher N, Mahnik SN, Fuerhacker M. 2005. Presence of cancerostatic platinum compounds in hospital wastewater and possible elimination by adsorption to activated sludge. Sci Total Environ 345:141-152.
84. Lenz K, Koellensperger G, Hann S, Weissenbacher N, Mahnik SN, Fuerhacker M. 2007. Fate of cancerostatic platinum compounds in biological wastewater treatment of hospital effluents. Chemosphere 69(11):765-774.
85. Liang X, Huang Y. 2002. Physical state changes of membrane lipids in human lung adenocarcinoma A(549) cells and their resistance to cisplatin. Int J Biochem Cell Biol 34:1248-1255.
86. Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D'Ambrosio S, Gibson-D'Ambrosio R, Chan KK. 2002a. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemother Pharmacol 49:367-374.
87. Liu J, Kraut EH, Balcerzak S, Grever M, D'Ambrosio S, Chan KK. 2002b. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat. Cancer Chemother Pharmacol 50:445-453.
88. Lustig L, Zang S, Michalke B, Schramel P, Beck W. 1997. Platinum determination in nutrient plants by inductively coupled plasma mass spectrometry with special respect to the hafnium oxide interference. Fresenius J Anal Chem 357:1157-1163.
89. Lustig S, de Kimpe J, Cornelis R, Schramel P. 1999. Development of native two-dimensional electrophoresis methods for the separation and detection of platinum carrying serum proteins: Initial steps. Fresenius J Anal Chem 363:484-487.
90. Mandal R, Jiang G, Li XF. 2003. Direct evidence for co-binding of cisplatin and cadmium to a native zinc- and cadmium-containing metal-lothionein. Appl Organometal Chem 17:675-681.
91. Mandal R, Kalke R, Li XF. 2003. Mass spectrometric studies of cisplatin-induced changes of hemoglobin. Rapid Commun Mass Spectrom 17: 2748-2754.
92. Mandal R, Teixeira C, Li XF. 2003. Studies of cisplatin and hemoglobin interactions using nanospray mass spectrometry and liquid chromatography with inductively-coupled plasma mass spectrometry. Analyst 128:629-634.
93. Mandal R, Kalke R, Li XF. 2004. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group. Chem Res Toxicol 17:1391-1397.
94. Mandal R, Sawyer MB, Li XF. 2006. Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses. Rapid Commun Mass Spectrom 20:2533-2538.
95. Mason HJ, Morton J, Garfitt SJ, Iqbal S, Jones K. 2003. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hyg 47:681-685.
96. Mason HJ, Blair S, Sams C, Jones K, Garfitt SJ, Cuschieri MJ, Baxter PJ. 2005. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg 49:603-610.
97. McCurdy E, Potter D. 2001. Optimising ICP-MS for the determination of trace metals in high matrix samples. Spectroscopy Europe 13:10-13.
98. McDonald ES, Randon KR, Knight A, Windebank AJ. 2005. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity. Neurobiol Dis 18:305-313.
99. Meczes EL, Azim-Araghi A, Ottley CJ, Pearson DG, Tilby MJ. 2005. Specific adducts recognised by a monoclonal antibody against cisplatinmodified DNA. Biochem Pharmacol 70:1717-1725.
100. Messori L, Orioli P, Vullo D, Alessio E, Iengo E. 2000. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin. Eur J Biochem 267:1206-1213.
101. Minakata K, Nozawa H, Okamoto N, Suzuki O. 2006. Determination of platinum derived from cisplatin in human tissues using electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 832:286-291.
102. Minami T, Hashii K, Tateyama I, Kadota E, Tohno Y, Tohno S, Utsumi M, Yamada MO, Ichii M, Namikawa K. 1994. Accumulation of platinum in the intervertebral discs and vertebrae of ovarian tumor-bearing patients treated with cisplatin. Biol Trace Elem Res 42:253-257.
103. Minami T, Ichii M, Okazaki Y. 1995. Comparison of three different methods for measurement of tissue platinum level. Biol Trace Elem Res 48:3744.
104. Morazzoni F, Canevali C, Moschetti I, Todeschini R, Caroli S, Alimonti A, Petrucci F, Ravasi G, Bedini AV, Milani F. 1995. Determination of platinum in plasma of patients alfected by inoperable lung carcinoma treated with radiotherapy and concurrent low-dose continuous infusion of cis-dichlorodiammine platinum(II). Cancer Chemother Pharmacol 35:529-532.
105. Morazzoni F, Canevali C, Zucchetti M, Caroli S, Alimonti A, Petrucci F, Giudice G, Masoni E, Bedini AV. 1998. cis-Diamminedichloroplatinum(II) given in low-dose continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: A pharmacokinetic approach. J Cancer Res Clin Oncol 124:37-43.
106. Morrison JG, Bissett D, Stephens IFD, McKay K, Brown R, Graham MA, Fichtinger-Schepman AM, Kerr DJ. 1993. The isolation and identification of cis-diamminedichloroplatinum(II)-DNA adducts by anion exchange HPLC and inductively coupled plasma mass spectrometry. Int J Oncol 2:33-37.
107. Morrison JG, White P, McDougall S, Firth JW, Woolfrey SG, Graham MA, Greenslade D. 2000. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: Application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 24:1 -10.
108. Nonose N, Kubota M. 2001. Non-spectral and spectral interferences in inductively coupled plasma high-resolution mass spectrometry. Part I. Optical characteristics of micro-plasmas observed just behind the sampler and the skimmer in inductively coupled plasma high resolution mass spectrometry. J Anal Atom Spectrom 16:551-559.
109. Nygren O, Vaughan GT, Florence TM, Morrison GM, Warner IM, Dale LS. 1990. Determination of platinum in blood by adsorptive voltammetry. Anal Chem 62:1637-1640.
110. Oe T, Tian Y, O'Dwyer PJ, Roberts DW, Malone MD, Bailey CJ, Blair IA. 2002. A validated liquid chromatography/tandem mass spectrometryassay for cis-amminedichloro(2-methylpyridine)platinum(II) in human plasma ultrafiltrate. Anal Chem 74:591 - 599.
111. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. 2007. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25:708-714.
112. Pasqua AJ, Goodisman J, Kerwood DJ, Toms BB, Dubowy RL, Dabrowiak JC. 2007. Role of carbonate in the cytotoxicity of Carboplatin. Chem Res Toxicol 20:896-904.
113. Perry BJ, Balazs RE. 1994. ICP-MS method for the determination of platinum in suspensions of cells exposed to cisplatin. Anal Proc Incl Anal Commun 31:269-271.
114. Pluim D, van Waardenburg RC, Beijnen JH, Schellens JH. 2004. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines. Cancer Chemother Pharmacol 54:71-78.
115. Pohlen U, Rieger H, Meyer BT, Loddenkemper C, Buhr HJ, Heitland P, Koester HD, Schneider P. 2007. Chemoembolization of lung metastases - Pharmacokinetic behaviour of carboplatin in a rat model. Anticancer Res 27:809-815.
116. Polec-Pawlak K, Abramski JK, Semenova O, Hartinger CG, Timerbaev AR, Keppler BK, Jarosz M. 2006. Platinum group metallodrug-protein binding studies by capillary electrophoresis - Inductively coupled plasma-mass spectrometry: A further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins. Electrophoresis 27:1128-1135.
117. Pongratz M, Schluga P, Jakupec MA, Arion VB, Hartinger CG, Allmaier G, Keppler BK. 2004. Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KPl019, studied by means of AAS, ESI-MS and CD spectroscopy. J Anal Atom Spectrom 19:46-51.
118. Rademaker-Lakhai JM, van den BD, Pluim D, Beijnen JH, Schellens JH. 2004. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole- tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res 10:3717-3727.
119. Reedijk J. 1999. Why does Cisplatin reach Guanine-N7 with competing S-donor ligands available in the cell? Chem Rev 99:2499-2510.
120. Rice JR, Gerberich JL, Nowotnik DP, Howell SB. 2006. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res 12: 2248-2254.
121. Rietz B, Heydorn K, Krarup-Hansen A. 1994. Determination of platinum by neutron activation analysis in nerve tissue from rats treated with cisplatin. Biol Trace Elem Res 43-45:343-350.
122. Robbins ME, Bywaters TB, Jaenke RS, Hopewell JW, Matheson LM, Tothill P, Whitehouse E. 1992. Long-term studies of cisplatin-induced reductions in porcine renal functional reserve. Cancer Chemother Pharmacol 29:309-315.
123. Rodushkin I, Engstrom E, Stenberg A, Baxter DC. 2004. Determination of low-abundance elements at ultra-trace levels in urine and serum by inductively coupled plasma-sector field mass spectrometry. Anal Bioanal Chem 380:247 - 257.
124. Rosenberg B, Vancamp L, Krigas T. 1965. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698-699.
125. Rosing H, Man WY, Doyle E, Bult A, Beijnen JH. 2000. Bioanalytical liquid chromatography method validation: A review of current practices and procedures. J Liq Chrom Rel Technol 23:329-354.
126. Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, Chaigneau L, Samain E, Chauffert B, Heyd B, Kantelip JP, Pivot X. 2005. Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: Influence of protein binding. Anticancer Drugs 16:1009-1016.
127. Rudolph E, Hann S, Stingeder G, Reiter C. 2005. Ultra-trace analysis of platinum in human tissue samples. Anal Bioanal Chem 382:1500-1506.
128. Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB. 2007. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother Pharmacol 59:301-312.
129. Scheulen ME, Kynast B, Jaehde U, Hilger RA, Scheuch E, Arion V, Kupsch P, Henke MM, Dittrich C, Keppler BK. 2004. A phase I dose-escalation trial with the new redox activated compound sodium irans-[tetrachlorobis(1 H-indazole)ruthenate(III)]/indazolhydrochloride (1:1.1) (FFC14A) in patients with solid tumors - A CESAR study. J Clin Oncol 22:2101 (ASCO Annual Meeting Proceedings).
130. Screnci D, Galettis P, Baguley BC, McKeage MJ. 1998. Optimization of an ICP-MS assay for the detection of trace levels of platinum in peripheral nerves. Atom Spectrosc 19:172-1175.
131. Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC. 2000. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 82:966-972.
132. Seifert WE Jr, Stewart DJ, Benjamin RS, Caprioli RM. 1983. Energy-dispersive X-ray fluorescence determination of platinum in plasma, urine, and cerebrospinal fluid of patients administered cis- dichlorodiammineplatinum(II). Cancer Chemother Pharmacol 11:120-123.
133. Sessa C, Minoia C, Ronchi A, Zucchetti M, Bauer J, Borner M, de Jong J, Pagani O, Renard J, Weil C, D'Incalci M. 1998. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 9:1315-1322.
134. Sessa C, Capri G, Gianni L, Peccatori F, Grasselli G, Bauer J, Zucchetti M, Vigano L, Gatti A, Minoia C, Liati P, Van den BS, Bernareggi A, Camboni G, Marsoni S. 2000. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann Oncol 11: 977-983.
135. Shearan P, Smyth MR. 1988. Comparison of voltammetric and graphite furnace atomic absorption spectrometric methods for the direct determination of inorganic platinum in urine. Analyst 113:609-612.
136. Sum BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. 2003. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51:43-52.
137. Smit T, Snyman JR, Neuse EW, Bohm L, van Rensburg CE. 2005. Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice. Anticancer Drugs 16:501-506.
138. Smith CJ, Wilson ID, Abou-Shakra F, Payne R, Grisedale H, Long A, Roberts D, Malone M. 2002. Analysis of a [14C]-labelled platinum anticancer compound in dosing formulations and urine using a combination of HPLC-ICPMS and flow scintillation counting. Chromatographia 55: S-151-S-155.
139. Smith CJ, Wilson ID, Abou-Shakra F, Payne R, Parry TC, Sinclair P, Roberts DW. 2003. A comparison of the quantitative methods for the analysis of the platinum-containing anticancer drug [cis-[amminedichloro(2-methylpyridine)] platinum(II)] (ZD0473) by HPLC coupled to either a triple quadrupole mass spectrometer or an inductively coupled plasma mass spectrometer. Anal Chem 75:1463-1469.
140. Stefanka Z, Hann S, Koellensperger G, Stingeder G. 2004. Investigation of the reaction of cisplatin with methionine in aqueous media using HPLC-ICP-DRCMS. J Anal Atom Spectrom 19:894-898.
141. Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seifert W, Loo TL. 1982. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 10:51-54.
142. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ. 2002. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936-942.
143. Sulyok M, Hann S, Hartinger CG, Keppler BK, Stingeder G, Koellensperger G. 2005. Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. J Anal Atom Spectrom 20:856-863.
144. Szpunar J, Makarov A, Pieper T, Keppler BK, Lobinski R. 1999. Investigation of metallodrug-protein interactions by size-exclusion
145. Ta LE, Espeset L, Podratz J, Windebank AJ. 2006. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27:992-1002.
146. Thomas R. 2002. A beginner's guide to ICP-MS: Part XII - A review of interferences. Spectroscopy 17:24-31.
147. Thompson JJ, Houk RS. 1987. A study of internal standardization in inductively coupled plasma-mass spectrometry. Appl Spectrosc 41: 801806.
148. Timerbaev AR, Aleksenko SS, Polec-Pawlak K, Ruzik R, Semenova O, Hartinger CG, Oszwaldowski S, Galanski M, Jarosz M, Keppler BK. 2004. Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: Characterization of interactions between Pt(II) complexes and human serum albumin. Electrophoresis 25:1988-1995.
149. Timerbaev AR, Foteeva LS, Rudnev AV, Abramski JK, Polec-Pawlak K, Hartinger CG, Jarosz M, Keppler BK. 2007. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE. Electrophoresis 28:2235-2240.
150. Todoli JL, Mermet JM. 2006. Sample introduction systems for the analysis of liquid microsamples by ICP-AES and ICP-MS. Spectrochimica Acta Part B 61:239-283.
151. Tothill P, Matheson LM, Smyth JF. 1990. Inductively coupled plasma mass spectrometry for the determination of platinum in animal tissue and a comparison with atomic absorption spectrometry. J Anal Atom Spectrom 5:619-622.
152. Tothill P, Matheson LM, Robbins ME, Hopewell JW, McKay K, Smyth JF. 1992a. Long-term retention and distribution of platinum in animals after cisplatin administration. Cancer Ther Control 2:275-287.
153. Tothill P, Klys HS, Matheson LM, McKay K, Smyth JF. 1992b. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer therapy. Eur J Cancer 28:1358-1361.
154. Turci R, Sottani C, Ronchi A, Minoia C. 2002. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol Lett 134:57-64.
155. Turci R, Sottani C, Spagnoli G, Minoia C. 2003. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: A review of analytical methods. J Chromatogr B Analyt Technol Biomed Life Sci 789:169-209.
156. U.S.Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry, Bioanalytical Method Validation. 2001. FDA. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Guidance for Industry: Bioanalytical Method Validation http://www.fda gov/cder/guidance/4252fhl.pdf.
157. Vacchina V, Torti L, Allievi C, Lobinski R. 2003. Sensitive species-specific monitoring of a new triplatinum anti-cancer drug and its potential related compounds in spiked human plasma by cation-exchange HPLC-ICP-MS. J Anal Atom Spectrom 18:884-890.
158. Vanhaecke F, Saverwyns S, de Wannemacker G, Moens L, Dams R. 2000. Comparison of the application of higher mass resolution and cool plasma conditions to avoid spectral interferences in Cr(III)/Cr(VI) speciation by means of high-performance liquid chromatography-inductively coupled plasma mass spectrometry. Anal Chim Acta 419: 55-64.
159. Vermorken JB, van der Vijgh WJ, Pinedo HM. 1980. Pharmacokinetic evidence for an enterohepatic circulation in a patient treated with cis- dichlorodiammineplatinum (II). Res Commun Chem Pathol Pharmacol 28:319-328.
160. Vrana O, Brabec V, Kleinwachter V. 1986. Polarographic studies on the conformation of some platinum complexes: Relations to anti-tumour activity. Anticancer Drug Des 1:95-109.
161. Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM. 1999. Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. Biochem Pharmacol 58:1057-1066.
162. Wang K, Lu J, Li R. 1996. The events that occur when cisplatin encounters cells. Coord Chem Rev 151:53-88.
163. Wittgen BP, Kunst PW, Perkins WR, Lee JK, Postmus PE. 2006. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med 19:385-391.
164. Xie R, Johnson W, Rodriguez L, Gounder M, Hall GS, Buckley B. 2007. A study of the interactions between carboplatin and blood plasma proteins using size exclusion chromatography coupled to inductively coupled plasma mass spectrometry. Anal Bioanal Chem 387:2815-2822.
165. Xilei L, Heydorn K, Rietz B. 1992. Limit of detection for the determination of Pt in biological material by RNAA using electrolytic separation of gold. J Radioanal Nucl Chem 160:85-99.
166. Yamada K, Kato N, Takagi A, Koi M, Hemmi H. 2005. One-milliliter wetdigestion for inductively coupled plasma mass spectrometry (ICP-MS): Determination of platinum-DNA adducts in cells treated with platinum(II) complexes. Anal Bioanal Chem 382:1702-1707.
167. Yang Z, Hou X, Jones BT 2002. Determination of platinum in clinical samples. Appl Spectrosc Rev 37:57-88.
168. Zhang J, Zhao X. 2007. Synthesis, cytotoxicity and DNA-binding levels of ammine/propylamine platinum(II) complexes with carboxylates. Eur J Med Chem 42:286-291.
169. Zhao Z, Tepperman K, Dorsey JG, Elder RC. 1993. Determination of cisplatin and some possible metabolites by ion-pairing chromatography with inductively coupled plasma mass spectrometric detection. J Chromatogr 615:83-89.
170. Zhao YY, Mandal R, Li XF. 2005. Intact human holo-transferrin interaction with oxaliplatin. Rapid Commun Mass Spectrom 19:1956-1962.
171. Ziegler E, Mason HJ, Baxter PJ. 2002. Occupational exposure to cytotoxic drugs in two UK oncology wards. Occup Environ Med 59:608-612.
172. Zoorob GK, McKiernan JW, Caruso JA. 1998. ICP-MS for elemental speciation studies. Mikrochim Acta 128:145-168.
173. Zoriy M, Matusch A, Spruss T, Becker S. 2007. Laser ablation inductively coupled plasma mass spectrometry for imaging of copper, zinc, and platinum in this sections of a kidney from a mouse treated with cisplatin. Int J Mass Spectrom 260:102-106.